Tag: restrictions

MONTRÉAL, June 04, 2026 (GLOBE NEWSWIRE) -- Boralex Inc. ("Boralex" or the "Corporation") (TSX: BLX) is pleased to announce that its shareholders have approved, at the annual and special meeting held on June 4, 2026 (the "Meeting"), a special resolution (the "Arrangement Resolution") approving the statutory plan of arrangement for the acquisition by BIF Thunder Holdings Inc., a newly-formed entity to be jointly owned by Brookfield Infrastructure Fund V and/or its affiliates (collectively, "Brookfield") and Caisse de dépôt et placement du Québec ("La Caisse"), of all the issued and outstanding Class A common shares of Boralex (the "Shares") at $37.25 in cash per Share (the "Arrangement").

MONTRÉAL, 04 juin 2026 (GLOBE NEWSWIRE) -- Boralex inc. (« Boralex » ou la « Société ») (TSX : BLX) est heureuse d’annoncer que ses actionnaires ont approuvé, à l’assemblée annuelle et extraordinaire tenue le 4 juin 2026 (l’« assemblée »), une résolution spéciale (la « résolution relative à l’arrangement ») qui approuve le plan d’arrangement prévu par la loi visant l’acquisition par BIF Thunder Holdings Inc.,  une entité nouvellement constituée qui appartiendra conjointement à Brookfield Infrastructure Fund V et/ou aux membres du même groupe (collectivement, « Brookfield ») et à la Caisse de dépôt et placement du Québec (« La Caisse »), de toutes les actions ordinaires de catégorie A émises et en circulation de Boralex (les « actions ») au prix de 37,25 $ en espèces par action (l’« arrangement »).

MONTREAL, June 04, 2026 (GLOBE NEWSWIRE) -- Saputo Inc. (TSX: SAP) (we, Saputo or the Company) reported today its financial results for the fourth quarter and fiscal year ended on March 31, 2026. All amounts in this news release are in millions of Canadian dollars (CDN), except per share amounts, unless otherwise indicated, and are presented according to International Financial Reporting Standards (IFRS) Accounting Standards. The results of the Dairy Division (Argentina), which were previously reported under the International Sector, have been classified as discontinued operations, with comparative information presented accordingly, and with its assets and liabilities presented as held for sale.

MONTREAL, June 04, 2026 (GLOBE NEWSWIRE) -- Saputo Inc. (TSX: SAP) (we, Saputo or the Company) reported today its financial results for the fourth quarter and fiscal year ended on March 31, 2026. All amounts in this news release are in millions of Canadian dollars (CDN), except per share amounts, unless otherwise indicated, and are presented according to International Financial Reporting Standards (IFRS) Accounting Standards. The results of the Dairy Division (Argentina), which were previously reported under the International Sector, have been classified as discontinued operations, with comparative information presented accordingly, and with its assets and liabilities presented as held for sale.

MONTRÉAL, 04 juin 2026 (GLOBE NEWSWIRE) -- Saputo inc. (TSX: SAP) (nous, Saputo ou la Société) a divulgué aujourd’hui ses résultats financiers pour le quatrième trimestre et l’exercice financier clos le 31 mars 2026. À moins d’avis contraire, tous les montants inclus dans ce communiqué de presse sont exprimés en millions de dollars canadiens (CAD), sauf les données par action, et sont présentés conformément aux Normes internationales d’information financière (IFRS). Les résultats de la Division Produits laitiers (Argentine), qui étaient auparavant présentés dans le Secteur International, ont été classés comme des activités abandonnées. Les informations comparatives ont été présentées en conséquence tandis que les actifs et passifs ont été présentés comme étant détenus en vue de la vente.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE IN THIS STOCK EXCHANGE RELEASE BELOW.
Series 1 tranche 1 offering of UAB „Atsinaujinančios energetikos investicijos“ notes under the EUR 25 million Bonds Programme is extended until 11-06-2026:
Closed – End Investment Company Intended for Informed Investors UAB “Atsinaujinančios energetikos investicijos” (hereinafter, the “Company”) is extending its public offering of series 1 tranche 1 EUR 2026/2027 Notes (ISIN LT000013780, hereinafter the “Notes”) until 11 June 2026, moving forward also the issue date of the Notes to 15 June 2026 and their maturity term to 15 July 2027. The Notes are being issued under the EUR 25 million Bond Programme. The base prospectus of the programme (hereinafter, the “Prospectus”) was approved by the Bank of Lithuania on 18 May 2026 and announced by the Company.
According to the final terms of the series 1 tranche 1, approved by the Company (hereinafter, the “Final Terms”, amended terms are attached, together with the Issue Specific Summary and translations thereof into Lithuanian, Latvian and Estonian), the Company is planning to issue up to EUR 5 million of nominal value Notes maturing on 15 July 2027 to investors in Lithuania, Latvia and Estonia.
Summary of the main issue terms:
Series 1 tranche 1 size: up to EUR 5,000,000
Denomination: EUR 1,000
Issue price of the Note: EUR 1,000
Interest rate: 9%
Subscription period: from 20 May 2026 to 11 June 2026 2:30 pm Vilnius time
Settlement and issue date: 15 June 2026
Maturity date: 15 July 2027
Investors wishing to submit a subscription order must contact their brokerage company. The investors, having provided their orders for participation in the offering, should not do anything additionally and their orders are valid, unless they would like to withdraw them, as indicated in the final terms.

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).